Future directions in the treatment of Parkinson's disease

Movement Disorders

Volumn 22, Issue SUPPL. 17, 2007, Pages

  Schapira, Anthony H V ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adenosine A2a antagonists; Dopamine agonists; MAOB inhibitors; Neuroprotection; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; AMANTADINE; DJ 1 PROTEIN; DOPAMINE RECEPTOR STIMULATING AGENT; FIPAMEZOLE; FLUOXETINE; IDAZOXAN; ISTRADEFYLLINE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; METHAMPHETAMINE; MIRTAZAPINE; PARKIN; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE; UBIDECARENONE;

ANXIETY; BRADYKINESIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DRUG EFFECT; DYSKINESIA; FOLLOW UP; GENE MUTATION; HUMAN; LOCOMOTION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RIGIDITY; SUSTAINED DRUG RELEASE; TREMOR;

CHOLINERGIC ANTAGONISTS; COENZYMES; DOPAMINE AGONISTS; DRUG THERAPY; FORECASTING; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; UBIQUINONE;

EID: 36248974676     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21679     Document Type: Conference Paper

References (85)

1. Schapira AH. Science, medicine, and the future: Parkinson's disease. BMJ 1999;318:311-314.
2. Schapira AH. Etiology of Parkinson's disease. Neurology 2006;66 (Suppl 4):S10-S23.
3. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA 1999;281:341-346.
4. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005;365:415-416.
5. Olanow CW, Schapira AH, Agid Y. Neurodegeneration and prospects for neuroprotection and rescue in Parkinson's disease. Ann Neurol 2003;53 (Suppl 3):S1-S2.
6. McNaught KS, Olanow CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol 2003;53 (Suppl 3):S73-S84.
7. Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 2003;53 (Suppl 3):S61-S70.
8. Mytilineou C, Cohen G. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J Neurochem 1985;45:1951-1953.
9. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP Parkinsonism. J Neurosci Res 1991;30:666-672.
10. Chiueh CC, Huang SJ, Murphy DL. Enhanced hydroxyl radical generation by 2′-methyl analog of MPTP: suppression by clorgyline and deprenyl. Synapse 1992;11:346-348.
11. Wu RM, Chiueh CC, Pert A, Murphy DL. Apparent antioxidant effect of 1-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur J Pharmacol 1993;243:241-247.
12. Wu RM, Chen RC, Chiueh CC. Effect of MAO-B inhibitors on MPP+ toxicity in vivo. Ann NY Acad Sci 2000;899:255-261.
13. Tatton WG, Ju WY, Holland DP, Tai C, Kwan M. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994;63:1572-1575.
14. Wadia JS, Chalmers-Redman RM, Ju WJ, et al. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl. J Neurosci 1998;18:932-947.
15. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
16. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
17. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol anti-oxidative therapy of Parkinsonism trial. Ann Neurol 2002;51:604-612.
18. Ives NJ, Stowe RL, Marro J, et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004;329:593.
19. Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 2002;326:105-108.
20. Maruyama W, Takahashi T, Youdim M, Naoi M. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 2002;109:467-481.
21. Jenner P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology 2004;63 (Suppl 2):S13-S22.
22. Am OB, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 2004;355:169-172.
23. Youdim MB, Wadia A, Tatton W, Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 2001;939:450-458.
24. Schapira AH. Rasagiline. Nat Rev Drugs Discov 2005;4:625-626.
25. Rascol O. Monoamine oxidase inhibitors - is it time to up the TEMPO? Lancet Neurol 2003;2:142-143.
26. Ogawa N, Tanaka K, Asanuma M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 1994;657:207-213.
27. Muralikrishnan D, Mohanakumar KP. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998;12:905-912.
28. Kondo T, Ito T, Sugita Y. Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann NY Acad Sci 1994;738:222-229.
29. Finotti N, Castagna L, Moretti A, Marzatico F. Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment. Pharmacol Res 2000;42:287-291.
30. Yoshioka M, Tanaka K, Miyazaki I, et al. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neurosci Res 2002;43:259-267.
31. Nishibayashi S, Asanuma M, Kohno M, Gomez-Vargas M, Ogawa N. Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem 1996;67:2208-2211.
32. Gomez-Vargas M, Nishibayashi-Asanuma S, Asanuma M, Kondo Y, Iwata E, Ogawa N. Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res 1998;790:202-208.
33. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 1999;838:51-59.
34. Clow A, Freestone C, Lewis E, Dexter D, Sandler M, Glover V. The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase. Neurosci Lett 1993;164:41-43.
35. Kakimura J, Kitamura Y, Takata K, Kohno Y, Nomura Y, Taniguchi T. Release and aggregation of cytochrome c and α-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur J Pharmacol 2001;417:59-67.
36. Gu M, Iravani MM, Cooper JM, King D, Jenner P, Schapira AH. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem 2004;91:1075-1081.
37. Iravani MM, Haddon CO, Cooper JM, Jenner P, Schapira AH. Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem 2006;96:1325-1321.
38. Zou L, Jankovic J, Rowe DB, Xie W, Appel SH, Le W. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci 1999;64:1275-1285.
39. Kitamura Y, Kosaka T, Kakimura JI, et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4- phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol Pharmacol 1998;54:1046-1054.
40. Gassen M, Gross A, Youdim MB. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov Disord 1998;13:242-248.
41. Vu TQ, Ling ZD, Ma SY, et al. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. J Neural Transm 2000;107:159-176.
42. Takashima H, Tsujihata M, Kishikawa M, Freed WJ. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors. Exp Neurol 1999;159:98-104.
43. Nair VD, Olanow CW, Sealfon SC. Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 2003;373 (Part 1):25-32.
44. Sawada H, Ibi M, Kihara T, et al. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol 1998;44:110-119.
45. Du F, Li R, Huang Y, Li X, Le W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci 2005;22:2422-2430.
46. The Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
47. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
48. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004;291:358-364.
49. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003;60:381-389.
50. Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci 1993;16:439-444.
51. Agid Y, Olanow CW, Mizuno Y. Levodopa: why the controversy? Lancet 2002;360:575.
52. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
53. Wooten GF. Agonists vs levodopa in PD: the thrilla of whitha. Neurology 2003;60:360-362.
54. Albin RL, Frey KA. Initial agonist treatment of Parkinson disease: a critique. Neurology 2003;60:390-394.
55. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550.
56. Grondin R, Zhang Z, Yi A, et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced Parkinsonian monkeys. Brain 2002;125 (Part 10):2191-2201.
57. Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000;290:767-773.
58. Kordower JH, Palfi S, Chen EY, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999;46:419-424.
59. Nutt JG, Burchiel KJ, Cornelia CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60:69-73.
60. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589-595.
61. Barker RA. Continuing trials of GDNF in Parkinson's disease. Lancet Neurol 2006;5:285-286.
62. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. The Cocharane Library (2) (4). Chichester (UK): Wiley; 2004.
63. Crosby NJ, Deane KH, Clarke CE. Amatadine for dyskinesia in Parkinson's disease. Chichester (UK): Wiley; 2003.
64. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:141-143.
65. Colpaert FC, Degryse AD, Van Craenendonck HV. Effects of an α2 antagonist in a 20-year-old Java monkey with MPTP-induced Parkinsonian signs. Brain Res Bull 1991;26:627-631.
66. Grondin R, Hadj TA, Doan VD, Ladure P, Bedard PJ. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol 2000;361:181-186.
67. Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-Parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 1999;14:744-753.
68. Savola JM, Hill M, Engstrom M, et al. Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 2003;18:872-883.
69. Peyro-Saint-Paul H, Rascol O, Blin O, et al. A pilot study of idazoxan, an α2 antagonist, in Parkinson's disease. Mov Disord 1996;11:116.
70. Rascol O, Arnulf I, Brefe C, et al. L-dopa-induced dyskinesias improvement by an α2 antagonist, idazoxan, in patients with Parkinson's disease. Mov Disord 1991;12:111.
71. Pact V, Giduz T. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology 1999;53:1154.
72. Durif F, Vidailhet M, Bonnet AM, Blin J, Agid Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995;45:1855-1858.
73. Gomez-Mancilla B, Bedard PJ. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 1993;16:418-427.
74. Gony M, Lapeyre-Mestre M, Montastruc JL. Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol 2003;26:142-145.
75. Mori A, Shindou T. Physiology of adenosine receptors in the striatum regulation of striatal projection neurons. In: Kase H, Richrdson PJ, Jenner P, editors. Adenosine receptors and Parkinson's disease. San Siego, CA: Academic Press; 2000. pp 10-20.
76. Ochi M, Koga K, Kurokawa M, Kase H, Nakamura J, Kuwana Y. Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 2000;100:53-62.
77. Hauber W, Neuscheler P, Nagel J, Muller CE. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats. Eur J Neurosci 2001;14:1287-1293.
78. Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl) 1999;147:90-95.
79. Wardas J, Konieczny J, Lorenc-Koci E. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts Parkinsonian-like muscle rigidity in rats. Synapse 2001;41:160-171.
80. Carta AR, Pinna A, Tronci E, Morelli M. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. Neurology 2003;61 (Suppl 6):S39-S43.
81. Koga K, Kurokawa M, Ochi M, Nakamura J, Kuwana Y. Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol 2000;408:249-255.
82. Pinna A, Fenu S, Morelli M. Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 2001;39:233-238.
83. Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys. Ann Neurol 1998;43:507-513.
84. Schapira AH, Bezard E, Brotchie J, et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Disc 2006;5:845-854.
85. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-245.